Literature DB >> 25584709

Three-way Comparison of Whole-Body MR, Coregistered Whole-Body FDG PET/MR, and Integrated Whole-Body FDG PET/CT Imaging: TNM and Stage Assessment Capability for Non-Small Cell Lung Cancer Patients.

Yoshiharu Ohno1, Hisanobu Koyama, Takeshi Yoshikawa, Daisuke Takenaka, Shinichiro Seki, Masao Yui, Hitoshi Yamagata, Kota Aoyagi, Sumiaki Matsumoto, Kazuro Sugimura.   

Abstract

PURPOSE: To prospectively compare the capabilities for TNM classification and assessment of clinical stage and operability among whole-body magnetic resonance (MR) imaging, coregistered positron emission tomographic (PET)/MR imaging with and without MR signal intensity (SI) assessment, and integrated fluorine 18 fluorodeoxyglucose (FDG) PET/computed tomography (CT) in non-small cell lung cancer (NSCLC) patients.
MATERIALS AND METHODS: The institutional review board approved this study, and written informed consent was obtained from each patient. One hundred forty consecutive NSCLC patients (75 men, 65 women; mean age, 72 years) prospectively underwent whole-body MR imaging, FDG PET/CT, conventional radiologic examinations, and surgical, pathologic, and/or follow-up examinations. All factors and clinical stage and operability were then visually assessed. All PET/MR examinations were assessed with and without SI assessment. One examination used anatomic, metabolic, and relaxation-time information, and the other used only anatomic and metabolic information. κ statistics were used for assessment of all factors and clinical stages with final diagnoses. McNemar test was used to compare the capability of all methods to assess operability.
RESULTS: Agreements of assessment of every factor (κ = 0.63-0.97) and clinical stage (κ = 0.65-0.90) were substantial or almost perfect. Regarding capability to assess operability, accuracy of whole-body MR imaging and PET/MR imaging with SI assessment (97.1% [136 of 140]) was significantly higher than that of MR/PET without SI assessment and integrated FDG PET/CT (85.0% [119 of 140]; P < .001).
CONCLUSION: Accuracies of whole-body MR imaging and PET/MR imaging with SI assessment are superior to PET/MR without SI assessment and PET/CT for identification of TNM factor, clinical stage, and operability evaluation of NSCLC patients. RSNA, 2015

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25584709     DOI: 10.1148/radiol.14140936

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  20 in total

1.  Magnetic resonance imaging for staging of non-small-cell lung cancer-technical advances and unmet needs.

Authors:  Gregor Sommer; Bram Stieltjes
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

2.  PET/MRI and PET/CT: is there room for both at the top of the food chain?

Authors:  Torsten Kuwert; Philipp Ritt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-19       Impact factor: 9.236

3.  Getting published in Radiology: A Deputy Editor's perspective.

Authors:  Ali Guermazi; Herbert Y Kressel
Journal:  Jpn J Radiol       Date:  2015-08-05       Impact factor: 2.374

4.  Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies.

Authors:  Stuart A Taylor; Susan Mallett; Anne Miles; Stephen Morris; Laura Quinn; Caroline S Clarke; Sandy Beare; John Bridgewater; Vicky Goh; Sam Janes; Dow-Mu Koh; Alison Morton; Neal Navani; Alfred Oliver; Anwar Padhani; Shonit Punwani; Andrea Rockall; Steve Halligan
Journal:  Health Technol Assess       Date:  2019-12       Impact factor: 4.014

Review 5.  Clinical PET-MR Imaging in Breast Cancer and Lung Cancer.

Authors:  Samuel L Rice; Kent P Friedman
Journal:  PET Clin       Date:  2016-10

Review 6.  PET/MRI: Where might it replace PET/CT?

Authors:  Eric C Ehman; Geoffrey B Johnson; Javier E Villanueva-Meyer; Soonmee Cha; Andrew Palmera Leynes; Peder Eric Zufall Larson; Thomas A Hope
Journal:  J Magn Reson Imaging       Date:  2017-03-30       Impact factor: 4.813

Review 7.  FDG Whole-Body PET/MRI in Oncology: a Systematic Review.

Authors:  Hyun Woo Kwon; Ann-Katharina Becker; Jin Mo Goo; Gi Jeong Cheon
Journal:  Nucl Med Mol Imaging       Date:  2016-04-07

8.  Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer - does it change therapeutic decisions in comparison to 18F-FDG PET/CT?

Authors:  Benedikt M Schaarschmidt; Johannes Grueneisen; Martin Metzenmacher; Benedikt Gomez; Thomas Gauler; Christian Roesel; Philipp Heusch; Verena Ruhlmann; Lale Umutlu; Gerald Antoch; Christian Buchbender
Journal:  Eur Radiol       Date:  2016-05-14       Impact factor: 5.315

Review 9.  The developing role of FDG PET imaging for prognostication and radiotherapy target volume delineation in non-small cell lung cancer.

Authors:  Tom Konert; Jeroen B van de Kamer; Jan-Jakob Sonke; Wouter V Vogel
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 10.  PET/MRI in Oncological Imaging: State of the Art.

Authors:  Usman Bashir; Andrew Mallia; James Stirling; John Joemon; Jane MacKewn; Geoff Charles-Edwards; Vicky Goh; Gary J Cook
Journal:  Diagnostics (Basel)       Date:  2015-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.